4.6 Article

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment

Journal

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 148, Issue 3, Pages 633-645

Publisher

SPRINGER
DOI: 10.1007/s00432-021-03871-5

Keywords

Liposarcoma; Survivin; Inhibitor of apoptosis protein; Targeted therapy; Apoptosis

Categories

Funding

  1. Projekt DEAL

Ask authors/readers for more resources

The study demonstrated abundant expression of survivin in LPS, particularly in less-differentiated tumor subtypes. In vitro experiments showed that YM155, a survivin inhibitor, significantly reduced cell viability and induced apoptosis in dedifferentiated LPS (DDLPS) and pleomorphic LPS (PLS) cells. Additionally, combined treatment with doxorubicin or etoposide and YM155 enhanced cytotoxic effects on DDLPS and PLS cells.
Purpose Liposarcoma (LPS) represent the largest group of malignant soft tissue tumours comprising a heterogeneous group of subtypes in which the degrees of chemoresistance and radiosensitivity strongly vary. Consequently, it is of utmost interest to establish novel therapeutic regimens based on molecular targets. Methods Immunohistochemical staining of survivin was performed in tissue microarrays comprising 49 primary LPS specimens. LPS cell lines were treated with survivin antagonist YM155 and doxorubicin or etoposide alone as well as in combination. Changes in cell viability were investigated and the synergistic effect of a combined therapy analysed. Results Immunohistochemistry revealed an abundant expression of survivin in LPS that significantly concurred with less-differentiated tumour subtypes and grading. In vitro, we demonstrated the impact of the survivin inhibitor YM155 on dedifferentiated LPS (DDLPS) and, even more imposing, pleomorphic LPS (PLS) tumour cell viability with a strong induction of apoptosis. A combined treatment of doxorubicin or etoposide with YM155 augmented the cytotoxic effects on DDLPS and PLS cells. Conclusion These findings support the significant role of survivin in the oncogenesis and progression of LPS subtypes providing a rationale to target survivin in eligible in-vivo models and to pioneer clinical applications of survivin-specific substances unfolding their therapeutic potential in LPS patients prospectively.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available